285 related articles for article (PubMed ID: 31682239)
1. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.
Walsh SR; Simovic B; Chen L; Bastin D; Nguyen A; Stephenson K; Mandur TS; Bramson JL; Lichty BD; Wan Y
J Clin Invest; 2019 Dec; 129(12):5400-5410. PubMed ID: 31682239
[TBL] [Abstract][Full Text] [Related]
2. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
3. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.
Hübbe ML; Jæhger DE; Andresen TL; Andersen MH
Front Immunol; 2020; 11():578349. PubMed ID: 33101304
[TBL] [Abstract][Full Text] [Related]
4. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
5. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
6. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
Mondino A; Manzo T
Front Immunol; 2020; 11():1915. PubMed ID: 32973794
[TBL] [Abstract][Full Text] [Related]
7. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
[TBL] [Abstract][Full Text] [Related]
8. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
[TBL] [Abstract][Full Text] [Related]
9. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
10. Different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy.
Zhang S; Wang Q; Li WF; Wang HY; Zhang HJ; Zhu JJ
Eksp Onkol; 2004 Mar; 26(1):55-62. PubMed ID: 15112581
[TBL] [Abstract][Full Text] [Related]
11. Potent Antitumor T-Cell Memory Is Generated by Curative Viral Oncolytic Immunotherapy But Not Curative Chemotherapy.
Gao Y; Bergman I
Anticancer Res; 2018 Dec; 38(12):6621-6629. PubMed ID: 30504370
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
13. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.
Liu K; Caldwell SA; Greeneltch KM; Yang D; Abrams SI
J Immunol; 2006 Mar; 176(6):3374-82. PubMed ID: 16517705
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR phototherapy to enhance antitumor immune response and T cell immune memory.
Qi S; Lu L; Zhou F; Chen Y; Xu M; Chen L; Yu X; Chen WR; Zhang Z
Theranostics; 2020; 10(4):1814-1832. PubMed ID: 32042338
[TBL] [Abstract][Full Text] [Related]
15. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
16. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer.
Magalhaes I; Carvalho-Queiroz C; Hartana CA; Kaiser A; Lukic A; Mints M; Nilsson O; Grönlund H; Mattsson J; Berglund S
Expert Opin Biol Ther; 2019 Aug; 19(8):811-827. PubMed ID: 30986360
[TBL] [Abstract][Full Text] [Related]
17. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
18. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract][Full Text] [Related]
19. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
Nesbeth Y; Conejo-Garcia JR
Clin Dev Immunol; 2010; 2010():139304. PubMed ID: 21076522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
